Report Overview

The Prostate cancer drugs market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

In Kenya, Prostate Cancer is the most common cancer among males with an Age-Standardized Incidence Rate (ASR) of 40.6 per 100,000). Prostate cancer is mostly asymptomatic in the early stages. In 80% of the cases, it is diagnosed after progression to an advanced stage with more aggressive tumours, when the prognosis is poor. According to GLOBOCAN 2020, the number of new cases reported were 3,412 which accounted for 21.9% of all cancer cases among men. Prostate cancer contributes remarkably to the mortality in Africa and is anticipated to continue increasing as a result of urbanization and growth in the population.



Market Drivers

The market is majorly driven by rise in the prevalence of prostate cancer among men in Kenya. Screening remains the key strategy for the reduction of mortality through early detection of prostate cancer among men considered at risk.

An increase in the investment in research for the development of therapeutic products to treat prostate tumours is expected to propel the market growth.

According to the Kenya Demographic Health Survey, the screening rate for prostate cancer is 3%, 4.3% and 2.6% among men aged 1549years, 4044years and 4549years, respectively.

However, despite high mortality occurring in developing countries like Kenya due to prostate cancer, the screening rates are still very low. This has been associated with various barriers including low knowledge, awareness level and negative beliefs. This contributes to restraining growth in the prostate cancer drug market.